Chemistry Ventures, the venture capital firm founded by veterans from Bessemer Venture Partners, Index Ventures, and Andreessen Horowitz, is closing a $500 million second fund. The raise comes as the firm builds on momentum from its debut vehicle and positions itself as a serious player in early-stage and growth-stage investing.
The founding team brought deep pedigree from three of venture's most respected institutions. Bessemer, Index, and a16z collectively have backed thousands of companies across multiple decades, giving Chemistry's partners credibility in pattern recognition and portfolio construction. The firm's first fund, which launched in 2021, likely demonstrated the investing thesis and returns necessary to attract this significantly larger second close.
A $500 million fund represents serious dry powder for the market. Chemistry can now deploy capital across multiple rounds, supporting companies from seed through Series C and beyond. This scale allows the firm to be a lead investor in competitive financing rounds rather than primarily sitting in follow-on positions. It also gives portfolio companies meaningful reserves to tap for future fundraising.
The fund size signals confidence from LPs in both the macro environment and Chemistry's specific investing edge. Large institutional investors typically commit to second funds only when first funds show strong performance and clear theses. Chemistry's backing from Bessemer, Index, and a16z alumni suggests the team brought institutional networks and deal flow advantages to their independent practice.
The venture landscape remains competitive at this capital level. Sequoia, Tiger Global, General Catalyst, and Greycroft all manage substantial funds and maintain significant brand pull with founders. Chemistry's positioning around founders who previously worked at these top-tier firms gives it a differentiation angle. The team understands how the best venture firms operate internally and can replicate operational excellence.
This raise comes during a period when mid-market venture funds face both opportunity and headwinds. While dry powder remains abundant, returns